← Back to Search

Other

VSJ-110 Solution for Dry Eye Syndrome

Phase 2

Recruiting

Research Sponsored by Vanda Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured over a 4-week treatment period

Awards & highlights

Study Summary

This trial aims to find out if a new medication called VSJ-110 is safe and effective in treating dry eye compared to a placebo.

Who is the study for?

This trial is for adults over 18 years old with dry eye syndrome who can follow the study's instructions and attend all visits. Participants must consent to the study rules and privacy regulations. Those using certain medications that are not allowed during the trial cannot participate.Check my eligibility

What is being tested?

The trial is testing VSJ-110, a potential new treatment for dry eye, against a placebo (a substance with no therapeutic effect). The goal is to see if VSJ-110 is safe and works better than taking nothing at all.See study design

What are the potential side effects?

While specific side effects of VSJ-110 aren't listed here, common side effects in trials like this may include temporary discomfort or irritation in the eyes, redness, blurred vision, or watery eyes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured over a 4-week treatment period

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured over a 4-week treatment period

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured over a 4-week treatment period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Schirmer's Tear Test

Secondary outcome measures

Eye Dryness Score (EDS) of the Visual Analogue Scale (VAS)

Ocular Staining

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: VSJ-110 SolutionExperimental Treatment1 Intervention

Group II: Placebo SolutionPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

VSJ-110

2020

Completed Phase 2

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor

61 Previous Clinical Trials

19,364 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies available for patients to participate in this trial?

"The clinical trial, as indicated on clinicaltrials.gov, is actively seeking participants. It was initially published on February 29th, 2024, and last revised on March 5th of the same year."

Answered by AI

What are the potential risks associated with VSJ-110 Solution for individuals?

"Based on our assessment at Power, the safety rating for VSJ-110 Solution is marked as 2 due to its Phase 2 trial status. While there is some data supporting safety, efficacy evidence remains lacking."

Answered by AI

What is the upper limit for patient enrollment in this particular clinical investigation?

"Indeed, information on clinicaltrials.gov confirms the ongoing patient recruitment for this research. The trial was initially listed on February 29th, 2024 and last modified on March 5th, 2024. It aims to enroll a total of 40 participants from one designated site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

2024. "A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06296966.

All > Paid Studies Boston > Dry Eye